<DOC>
	<DOCNO>NCT02993367</DOCNO>
	<brief_summary>Vascular cognitive impairment dementia ( VCIND ) common among aged tends progress dementia , proper large-scale intervention trial dedicate . VCIND cause subcortical ischemic small vessel disease ( hereinafter , subcortical VCIND ) represent relatively homogeneous disease process suitable target therapeutic trial investigate VCIND . Preclinical trial show Butylphthalide Soft Capsules effective cognitive impairment vascular origin . In randomized , double-blind , placebo-controlled trial , investigator apply fMRI study effect Butylphthalide Soft Capsules patient VCIND .</brief_summary>
	<brief_title>The Efficacy Butylphthalide Soft Capsules Patents With VCIND</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>3-n-butylphthalide</mesh_term>
	<criteria>Literate Han Chinese age 40 65 year MMSE â‰¥24 Normal slightly impaired activity daily live The MRI entry criterion follow : Subcortical small infarct ( 320 mm diameter ) , one strategically locate subcortical small infarct caudate nucleus globus pallidus , thalamus Absence cortical watershed infarct , hemorrhage , hydrocephalus , WMLs specific cause ( e.g. , multiple sclerosis ) ; No hippocampal entorhinal cortex atrophy ( score 0 accord medial temporal lobe atrophy scale Scheltens ) Patients Diabetes mellitus Disorders subcortical VCIND may affect cognition ; score Hamilton depression scale 17 schizophrenia Clinically significant gastrointestinal , renal , hepatic , respiratory , infectious , endocrine , cardiovascular system disease ; cancer ; alcoholism ; drug addiction ; use medication may affect cognitive function Known hypersensitivity celery Inability undergo brain MRI</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Butylphthalide Soft Capsules</keyword>
	<keyword>VCIND</keyword>
	<keyword>fMRI</keyword>
</DOC>